Newsfeeds Archive - Spark Newswire

2 minute read

BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant

April 1, 9:02 AM

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has

BLRX

3 minute read

Earnings

Earnings Scheduled For November 20, 2023

By Benzinga Insights

November 20, 8:11 AM

Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million.

1 minute read

Earnings

BioLine Rx Earnings Preview

By Benzinga Insights

November 17, 10:01 AM

BioLine Rx (NASDAQ:BLRX) is set to give its latest quarterly earnings report on Monday, 2023-11-20. Here’s what investors…

BLRX

1 minute read

BlueLinx Announces New $100M Share Repurchase Authorization

By Benzinga Newsdesk

October 31, 4:48 PM

BlueLinx Holdings Inc. (NYSE:BXC), a leading U.S.

BLRX

2 minute read

News

BioLineRx Entered Exclusive License Agreement To Motixafortide In Asia, Advisored By M.S.Q. Ventures; Provides $15M Upfront And Equity Investment Of $14.6M, Up To $50M In Development And Regulatory Milestones, Up To $200M In Commercial Milestones

By Benzinga Newsdesk

October 31, 9:05 AM

M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co.,

BLRX

1 minute read

News

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

By Benzinga Newsdesk

October 12, 7:05 AM

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the closing of an exclusive license agreement

BLRX

1 minute read

BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer

By Vandana Singh

September 28, 12:54 PM

BioLineRx Ltd (NASDAQ: BLRX) announced data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination trial of motixafortide and gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone, in first-line

BLRX

2 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for BioLine Rx: Here’s What You Need To Know

By Benzinga Insights

September 15, 1:00 PM

HC Wainwright & Co. has decided to maintain its Buy rating of BioLine Rx (NASDAQ:BLRX) and raise its…

BLRX

2 minute read

Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For Friday

By Lisa Levin

September 15, 7:17 AM

B of A Securities raised the price target for Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to close at $35.71 on Thursday.

ADBE